RxDoctor Payments DataLook up a doctor →

Amanda Bauer, APRN

Hematology & Oncology · Lincoln, NENPI 1053301317

Payments from drug & device makers

$4,588in general payments, 2019–2025

Across 239 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$412
  • AbbVie$325
  • Astellas Pharma US Inc$290
  • Seagen Inc.$263
  • Pfizer$263
  • Pharmacyclics LLC, An Abbvie Company$231
  • plus $3K from 52 others

What the payments were for

  • Food & beverage$4,21592%
  • Education$3738%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)19$412
AbbVie16$325
Astellas Pharma US Inc12$290
Seagen Inc.13$263
Pfizer15$263
Pharmacyclics LLC, An Abbvie Company12$231
Novartis13$228
Merck8$140
AstraZeneca7$139
Genentech USA, Inc.6$121
Daiichi Sankyo Inc.6$114
Tersera Therapeutics LLC4$110
Lilly USA, LLC7$98
Eisai Inc.6$96
Sanofi-aventis U.S. LLC1$90
Pharmacosmos Therapeutics Inc.4$89
Ipsen Biopharmaceuticals, Inc4$84
Taiho Oncology, Inc.4$80
Bristol Myers Squibb5$76
Bayer4$69
Genmab U.S., Inc.3$66
Regeneron Healthcare Solutions, Inc.3$65
Amgen4$63
Amneal Pharmaceuticals LLC2$61
AVEO Pharmaceuticals, Inc.4$61
Servier Pharmaceuticals LLC3$55
Pharmaessentia USA Corporation3$53
Iovance Biotherapeutics, Inc.2$50
Incyte Corporation3$46
Stemline Therapeutics Inc.3$44
G1 Therapeutics, Inc.3$40
Blueprint Medicines Corporation2$40
Clovis Oncology, Inc.3$38
Gilead(2 entities)2$37
Sumitomo Pharma America, Inc.2$35
Sanofi2$35
E.r. Squibb & Sons, L.L.C.2$34
Myovant Sciences Inc.2$34
GSK2$33
Karyopharm Therapeutics Inc.2$32
Adaptive Biotechnologies Corporation2$31
Davol Inc.1$30
Sobi, Inc2$29
CTI Biopharma Corp.2$28
Kyowa Kirin, Inc.1$23
Mirati Therapeutics, Inc.1$23
Ferring Pharmaceuticals Inc.1$21
EMD Serono, Inc.1$19
Takeda Pharmaceuticals U.S.A., Inc.1$19
Beone Medicines USA, Inc.1$17
Progenics Pharmaceuticals, Inc.1$16
Boston Scientific1$15
Coherus Oncology, Inc.1$14
Spectrum Pharmaceuticals Inc.1$14
Exelixis Inc.1$14
Novocure Inc.1$14
Array Biopharma Inc1$12
Dova Pharmaceuticals1$11

How this compares

$4,588 in reported general payments places this provider in the 35th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024
$12,877
Medicare patients
56
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$8,691
Fentanyl33$3,545
Oxycodone Hcl142$1,978
Morphine Sulfate ErMorphine Sulfate30$933
Dexamethasone24$660
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$621
Gabapentin31$363
Duloxetine Hcl31$254
Morphine Sulfate12$181
Omeprazole12$87
Lorazepam20$76
Ondansetron Hcl12$46

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Lincoln

See the full list for Nebraska →

Where these figures come from

Is this you, or does something look wrong? →